https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-22282023-07-28 00:00:002024-04-17 15:08:24Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-07 / Neurooncol Adv 2023;5(1):vdad081
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-07 / Neurooncol Adv 2023;5(1):vdad0812023-07-07 00:00:002023-07-07 00:00:00Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-05-03 / Hum Vaccin Immunother 2023 May;:2198467
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-05-03 / Hum Vaccin Immunother 2023 May;:21984672023-05-03 00:00:002023-05-03 00:00:00Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-624
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-6242023-04-21 00:00:002023-04-21 00:00:00Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-04-03 / Pharmaceutics 2023 Apr;15(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-04-03 / Pharmaceutics 2023 Apr;15(4)2023-04-03 00:00:002023-04-03 00:00:00The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-03-02 / NPJ Vaccines 2023 Mar;8(1):29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-03-02 / NPJ Vaccines 2023 Mar;8(1):292023-03-02 00:00:002023-05-30 16:16:10Autologous dendritic cell vaccination against HIV-1 induces changes in natural killer cell phenotype and functionality
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-02-13 / Cancers (Basel) 2023 Feb;15(4)2023-02-13 00:00:002023-05-30 16:20:40Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-31 / Expert Opin Drug Discov 2023 Jan;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-31 / Expert Opin Drug Discov 2023 Jan;2023-01-31 00:00:002023-01-31 00:00:00Glioblastoma treatment slowly moves towards change: novel druggable targets and translational horizons in 2022
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-20 / Strahlenther Onkol 2023 Jan;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-20 / Strahlenther Onkol 2023 Jan;2023-01-20 00:00:002023-01-20 00:00:00[Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-121
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-01-01 / JAMA Oncol 2023 Jan;9(1):112-1212023-01-01 00:00:002023-05-30 16:23:26Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
